NCT05426018Unknown2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluate the Efficacy and Safety of Oral Administration of Different Doses of SY-009 Capsule in Patients With T2DM for 12 Weeks
Suzhou Yabao Pharmaceutical R&D Co., Ltd.7 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 200
- 试验地点
- 7
- 主要终点
- Changes of HbA1c compared with baseline at 12 weeks
研究概览
简要总结
SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects were ≥ 18 years old and ≤ 75 years old at the first screening (visit 1);
- •At the first screening (visit 1) and the baseline period (visit 3), male weight ≥ 50kg, female weight ≥ 45kg, and body mass index (BMI) between 18.0 and 35.0 kg/m2 (including the critical value);
- •At the first screening (visit 1), the subjects had been diagnosed with type 2 diabetes for at least 3 months according to the WHO diagnostic criteria and classification in 1999;
- •The subjects had been receiving diet control and exercise therapy for 3 months before the first screening (visit 1), and had not received systematic treatment for diabetes during this period (the cumulative use of hypoglycemic drugs in recent 3 months was not more than 2 weeks, and no hypoglycemic drugs were used in recent 1 month);
- •The subjects' HbA1c at the first screening (visit 1) was between 7.5% and 10.5% (including the critical value); During the baseline period (visit 3), HbA1c was between 7.0% and 10.5% (including the critical value);
- •Subjects' fasting blood glucose ≤ 13.3mmol/l in the baseline period (visit 3);
- •Before the trial, the nature, significance, possible benefits, possible inconvenience, potential risks and discomfort of the trial have been understood in detail, and they have volunteered to participate in the clinical trial. They can communicate well with researchers, comply with the requirements of the whole trial, and have signed a written informed consent.
排除标准
- •Known allergic to the test drug (including the excipients of the test drug) or its analogues, or allergic constitution (such as allergic to two or more drugs, food and pollen), or having taken SGLT-1 or sglt-2 inhibitors in the past 1 year;
- •Received long-term (>2 weeks) systemic glucocorticoid therapy (excluding topical, ophthalmic or inhaled preparations) within 3 months before screening;
- •Diagnosed as type 1 diabetes, or gestational diabetes, or other special types of diabetes;
- •There is sufficient evidence of active diabetes proliferative retinopathy;
- •History of severe hypoglycemia (such as consciousness disorder and coma caused by hypoglycemia), or history of serious unconscious hypoglycemia;
- •History of acute metabolic complications of diabetes within 6 months before screening (diabetes ketoacidosis, hypertonic non ketoacidosis coma, diabetes lactic acidosis);
- •Serious trauma, serious infection or operation that may affect blood glucose control occurred within 1 month before screening;
- •There are obvious blood system diseases (such as aplastic anemia, myelodysplastic syndrome), or any disease that causes hemolysis or red blood cell instability (such as malaria), or hemoglobinopathy that may affect the determination of HbA1c level (such as sickle cell disease);
- •Have obvious autonomic neuropathy, such as urinary retention, postural hypotension, diabetes diarrhea or gastroparesis；
- •Habitual diarrhea, irritable bowel syndrome, clinically significant abnormal gastric emptying (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as active ulcer within 6 months) or gastrointestinal surgery within 3 months before screening;
- •History of organ transplantation (excluding corneal transplantation), or other acquired or congenital immune system diseases, or clinically significant peripheral vascular diseases;
- •History of heart failure (NYHA grade III and IV), or history of acute myocardial infarction or unstable angina pectoris within 6 months before screening; Or have a history of coronary angioplasty, coronary stent implantation or coronary artery bypass surgery within 6 months before screening or have a recent cardiac surgery plan;
- •In the screening period, when no pacemaker was installed, grade II or III atrioventricular block or qtcb interval was prolonged >500 MS in 12 lead ECG;
- •Patients with abnormal thyroid function (such as thiourea and thyroid hormone drugs) whose treatment dose was not stable within the first 6 months were screened; Hypothyroidism with poor control or history of hypothyroidism;
- •Unstable weight (weight change more than 5kg) within 2 months before screening, or used drugs with weight control effect or performed surgery that can lead to unstable weight, or is currently in the weight loss plan and is not in the maintenance stage;
- •Poor blood pressure control (systolic blood pressure (SBP) ≥ 160mmhg and / or diastolic blood pressure (DBP) ≥ 100 mmHg);
- •At the first screening (visit 1), the subjects were positive for HBsAg, HCV antibody, Treponema pallidum antibody or human immunodeficiency virus antibody;
- •The clinical laboratory test results at the first screening (visit 1) and the baseline period (visit 3) meet any of the following criteria: 1） Hemoglobin (Hgb) < 100g/l; 2） Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal value (ULN);3） Total bilirubin (TBIL) > 1.5 times the upper limit of normal value (except for the known Gilbert syndrome that meets the following requirements, that is, part of bilirubin indicates conjugated bilirubin < 35% of total bilirubin); 4） Triglyceride (TG) ≥ 5.7mmol/l; 5） Estimated glomerular filtration rate < 60 ml/min (estimated by CKD-EPI formula);
- •Regular drinking (weekly alcohol intake greater than 21 units (male) and 14 units / week (female) (1 unit = 360ml beer; 150ml wine; or 45ml Baijiu) within 3 months before screening, or unable to quit drinking during the test;
- •Those who lost more than 400 ml of blood / donated blood (except physiological blood loss of women) within 3 months before screening, received blood transfusion or used blood products, or planned to donate blood during the test or within 1 month (30 days) after the end of the test;
- •Patients with a history of needle fainting, blood fainting or inability to tolerate venipuncture；
- •History of drug abuse, drug abuse and addiction;
- •Patients with obvious mental disorders, epilepsy and other persons without behavioral ability or cognitive ability;
- •History of malignant tumor or currently suffering from any malignant tumor;
- •Female subjects in pregnancy, lactation or pregnancy test (blood HCG test) positive; And the subjects have fertility or sperm / egg donation plans during the test period and within 60 days after the end of the test and cannot take effective physical contraceptive measures (effective contraceptive measures include abstinence, sterilization, intrauterine device, or diaphragm method stipulated by local laws);
- •An intervention clinical trial has been completed or withdrawn within 1 month before screening, or is currently undergoing an intervention clinical trial, or has participated in other medical research activities, which is not suitable to participate in this trial according to the judgment of the researcher;
- •The subjects may not be able to complete the test for other reasons or the researchers think they should not be included.
研究组 & 干预措施
SY-009 -1
Experimental
0.5mg tid
干预措施: SY-009 capsules (Drug)
SY-009-2
Experimental
1.0mg tid
干预措施: SY-009 capsules (Drug)
SY-009-3
Experimental
1.5mg tid
干预措施: SY-009 capsules (Drug)
Placebo
Placebo Comparator
tid
干预措施: SY-009 capsules (Drug)
结局指标
主要结局
Changes of HbA1c compared with baseline at 12 weeks
时间窗: 12 weeks
Changes of HbA1c in each dose group compared with baseline at 12 weeks of treatment
次要结局
- Blood drug concentration level(4 weeks，8 weeks，12 weeks)
- Changes of HbA1c compared with baseline at 8 weeks(8 weeks)
- Changes of blood glucose at 2h after meal compared with baseline(4 weeks，8 weeks，12 weeks)
- Changes of blood glucose at 2h after breakfast compared with baseline(12 weeks)
- Change of GLP-1 from baseline 2h after breakfast(12 weeks)
- Change of mean fasting blood glucose from baseline(12 weeks)
- Change of fasting blood glucose from baseline(4 weeks，8 weeks，12 weeks)
- Changes of maximum blood glucose increase (0-180min) after breakfast compared with baseline at 12 weeks(12 weeks)
- Proportion of subjects with HbA1c ≤ 7%(8 weeks，12 weeks)
- Proportion of subjects with HbA1c ≤ 6.5%(8 weeks，12 weeks)
- Changes of insulin at 2h after breakfast compared with baseline(12 weeks)
- Changes of C-peptide at 2h after breakfast compared with baseline(12 weeks)
- Changes in insulin resistance (HOMA-IR) from baseline(12 weeks)
- Change of GIP from baseline 2h after breakfast(12 weeks)
- Islet of Langerhans β Cellular function (HOMA- β） Change from baseline(12 weeks)
- change of mean blood glucose value at 7 time points from baseline(4 weeks，8 weeks，12 weeks)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.CoughNCT01587716GlaxoSmithKline36
已完成
1 期
Patient Tolerability Study of GSK163090Depressive Disorder, MajorMajor Depressive Disorder (MDD)NCT00559299GlaxoSmithKline20
已完成
1 期
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)Diabetes Mellitus, Type 2NCT01223339Merck Sharp & Dohme LLC24
已完成
1 期
A Study of ACE-2494 in Healthy SubjectsHealthy VolunteersNCT03478319Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA48
进行中（未招募）
2 期
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney DiseaseDiabetic Kidney DiseaseIgA NephropathyNCT05687890Biocity Biopharmaceutics Co., Ltd.240